Compare
AbbVie vs Harmony Biosciences Holdings (ABBV vs HRMY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Harmony Biosciences Holdings (HRMY) +5.6%; so far this year the figures are +27.5% and -11.5%.
AbbVie is the larger company by market value, about 265.4 times the size of Harmony Biosciences Holdings.
On trailing earnings, ABBV trades at 50.1 times and HRMY at 10.9 times.
Revenue grew +10.7% at ABBV and +19.8% at HRMY over the last year.
ABBV yields 2.38%. HRMY pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | HRMY | |
|---|---|---|
| Price | $291.31 | $33.11 |
| 1-day | +1.07% | +1.97% |
| YTD | +27.49% | -11.52% |
| 1 year | +34.39% | +5.61% |
| 3 years | +104.47% | +35.03% |
| Market cap | $514.9B | $1.9B |
| P/E | 50.1 | 10.9 |
| P/S | 7.80 | 1.97 |
| P/B | — | 1.81 |
| Revenue growth | +10.70% | +19.80% |
| EPS growth | +340.20% | -4.70% |
| Gross margin % | 73.7 | 74.0 |
| Net margin % | 15.7 | 18.1 |
| ROE % | — | 16.7 |
| Debt / equity | — | 0.14 |
| FCF yield % | 3.7 | 16.6 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.59 |
| RSI (14) | 59.7 | 30.9 |
| Technical rating |